Flexion Therapeutics (NASDAQ:FLXN) has earned a consensus rating of “Buy” from the twelve brokerages that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $99.00.
A number of analysts have issued reports on the stock. Wells Fargo set a $39.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Tuesday, April 3rd. BidaskClub upgraded shares of Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, March 28th. BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (down from $37.00) on shares of Flexion Therapeutics in a report on Friday, March 9th. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 5th. Finally, Berenberg Bank assumed coverage on shares of Flexion Therapeutics in a report on Thursday, February 1st. They issued a “buy” rating and a $42.00 target price on the stock.
Institutional investors have recently bought and sold shares of the company. Schroder Investment Management Group boosted its stake in shares of Flexion Therapeutics by 21.0% during the 4th quarter. Schroder Investment Management Group now owns 516,981 shares of the specialty pharmaceutical company’s stock worth $12,945,000 after purchasing an additional 89,806 shares during the period. American Financial Group Inc. purchased a new position in shares of Flexion Therapeutics during the 4th quarter worth about $5,280,000. Guggenheim Capital LLC boosted its stake in shares of Flexion Therapeutics by 160.1% during the 4th quarter. Guggenheim Capital LLC now owns 117,759 shares of the specialty pharmaceutical company’s stock worth $2,948,000 after purchasing an additional 72,481 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Flexion Therapeutics during the 4th quarter worth about $7,712,000. Finally, Eaton Vance Management boosted its stake in shares of Flexion Therapeutics by 37.2% during the 4th quarter. Eaton Vance Management now owns 12,900 shares of the specialty pharmaceutical company’s stock worth $323,000 after purchasing an additional 3,500 shares during the period. Hedge funds and other institutional investors own 94.46% of the company’s stock.
NASDAQ FLXN traded down $0.36 on Friday, reaching $24.73. The company had a trading volume of 754,696 shares, compared to its average volume of 731,264. The company has a debt-to-equity ratio of 0.58, a quick ratio of 12.96 and a current ratio of 13.02. The company has a market cap of $930.32, a P/E ratio of -5.94 and a beta of 0.83. Flexion Therapeutics has a 12 month low of $16.51 and a 12 month high of $32.25.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.27). The business had revenue of $0.36 million for the quarter, compared to the consensus estimate of $1.29 million. analysts forecast that Flexion Therapeutics will post -5.18 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/22/flexion-therapeutics-flxn-receives-consensus-recommendation-of-buy-from-analysts.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.